Literature DB >> 22133608

Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.

Ignacio Casado Naranjo1, Juan Carlos Portilla-Cuenca, Pedro Enrique Jiménez Caballero, Maria Luisa Calle Escobar, Raúl Mauricio Romero Sevilla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22133608     DOI： 10.1159/000334578

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN： 1015-9770            Impact factor:   2.762


× No keyword cloud information.
  9 in total

1.  Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.

Authors:  James Douketis; Alan David Bell; John Eikelboom; Aaron Liew
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

2.  Thrombolysis in ischemic stroke patients on treatment with Dabigatran.

Authors:  Giuseppe Re; Danilo Toni
Journal:  Intern Emerg Med       Date:  2013-02-07       Impact factor: 3.397

3.  Is intravenous recombinant tissue plasminogen activator (r-tPA) safe in patients on Dabigatran?

Authors:  Raghav Govindarajan; Nestor Galvez
Journal:  J Vasc Interv Neurol       Date:  2014-05

Review 4.  Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.

Authors:  Amish N Raval; Joaquin E Cigarroa; Mina K Chung; Larry J Diaz-Sandoval; Deborah Diercks; Jonathan P Piccini; Hee Soo Jung; Jeffrey B Washam; Babu G Welch; Allyson R Zazulia; Sean P Collins
Journal:  Circulation       Date:  2017-02-06       Impact factor: 29.690

Review 5.  Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.

Authors:  T Steiner; M Böhm; M Dichgans; H-C Diener; C Ell; M Endres; C Epple; M Grond; U Laufs; G Nickenig; H Riess; J Röther; P D Schellinger; M Spannagl; R Veltkamp
Journal:  Clin Res Cardiol       Date:  2013-05-14       Impact factor: 5.460

6.  Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.

Authors:  Zikra Zulfiqar; Fawad Ali Shah; Shagufta Shafique; Abdullah Alattar; Tahir Ali; Arooj Mohsin Alvi; Sajid Rashid; Shupeng Li
Journal:  J Inflamm Res       Date:  2020-12-24

7.  Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases.

Authors:  Waltraud Pfeilschifter; Mario Abruscato; Susanne Hövelmann; Horst Baas
Journal:  Case Rep Neurol       Date:  2013-03-25

8.  Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly.

Authors:  Anders Helldén; Ingegerd Odar-Cederlöf; Göran Nilsson; Susanne Sjöviker; Anders Söderström; Mia von Euler; Gunnar Ohlén; Ulf Bergman
Journal:  BMJ Open       Date:  2013-04-11       Impact factor: 2.692

9.  Intravenous thrombolysis in a stroke patient receiving rivaroxaban.

Authors:  Felix Fluri; Florian Heinen; Christoph Kleinschnitz
Journal:  Cerebrovasc Dis Extra       Date:  2013-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.